Pharmacoeconomic Modeling of Prior-Authorization Intervention for COX-2 Specific Inhibitors in a 3-Tier Copay Plan

OBJECTIVES: To determine from a health plan perspective the cost-effectiveness of cyclooxygenase-2 (COX-2) specific inhibitors, with and without a prior-authorization (PA) process. METHODS: A modeling exercise was employed, based on prescription drug claims for a managed care organization with 3.8 m...

Descripción completa

Detalles Bibliográficos
Autores principales: Stacy, Jan, Shaw, Elizabeth, Arledge, Michele D., Howell-Smith, Donna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2003
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437282/
https://www.ncbi.nlm.nih.gov/pubmed/14613451
http://dx.doi.org/10.18553/jmcp.2003.9.4.327

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437282/
https://www.ncbi.nlm.nih.gov/pubmed/14613451
http://dx.doi.org/10.18553/jmcp.2003.9.4.327

Ejemplares similares